

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Bosentan hydrate

November 26, 2025

Therapeutic category

Other cardiovascular agents

Non-proprietary name

Bosentan hydrate

Safety measure

PRECAUTIONS should be revised.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
This English version is intended to be a reference material to provide convenience for users.
In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.

Current	Revision
<p>1. WARNINGS</p> <p>This drug causes hepatic function disorder. Patients must undergo liver function tests before administration and at least once a month during administration. It is desirable for patients to undergo the test once every 2 weeks for 3 months after the start of administration. If any abnormality is observed in liver function test values, appropriate measures such as dose reduction or discontinuation of administration should be taken according to the severity and clinical symptoms.</p> <p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>In the case where AST increased or ALT increased is accompanied by clinical symptoms of liver disorder, including queasy, vomiting, pyrexia, abdominal pain, jaundice, lethargy or fatigue, and flu-like symptoms (arthralgia, myalgia, pyrexia), or bilirubin level is 2 times the upper limit of the reference range or higher, administration should be discontinued.</p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions (newly added)</p>	<p>1. WARNINGS</p> <p>This drug <u>may</u> cause hepatic function disorder <u>or autoimmune hepatitis</u>. Patients must undergo liver function tests before administration and at least once a month during administration. It is desirable for patients to undergo the test once every 2 weeks for 3 months after the start of administration. If any abnormality is observed in liver function test values, appropriate measures such as dose reduction or discontinuation of administration should be taken according to the severity and clinical symptoms.</p> <p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>In the case where AST increased or ALT increased is accompanied by clinical symptoms of liver disorder <u>or autoimmune hepatitis</u>, including queasy, vomiting, pyrexia, abdominal pain, jaundice, lethargy or fatigue, and flu-like symptoms (arthralgia, myalgia, pyrexia), or bilirubin level is 2 times the upper limit of the reference range or higher, administration should be discontinued.</p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p><u>Autoimmune hepatitis</u> <u>Autoimmune hepatitis may occur with a latency of a few months to years after the start of administration of this drug.</u></p>

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.